CRE mRNA has been designed to produce high expression level of CRE recombinase fused to a nuclear localisation sequence (NLS). CRE mRNA encodes for the CRE recombinase is a type I topoisomerase from bacteriophage P1 that catalyses the site-specific recombination of DNA between two loxP sites. OZ Biosciences mRNAs are produced by in vitro transcription and stabilised at the 5' end by modified nucleotides capping (Cap1). These mature mRNAs contain a poly(A) tail at the 3' end and are also optimised to yield improved stability and performance.

• Ready-to-use stabilised CRE mRNA
• Concentration: 1.0mg/mL in 1mM sodium citrate, pH 6.4
• MRNA33 does not bear any additional nucleotide modifications
• MRNA32 is modified with 5-methoxyuridine (5moU) to reduce innate immune responses
• MRNA26 is modified with N1-methyl-pseudouridine (N1-mψ) to reduce innate immune response